News

PPD's X-Chem flips some potential drugs to partner Navitor

X-Chem, PPD's in-house biotech company, struck a deal with pioneering startup Navitor Pharmaceuticals, outlicensing some early-stage compounds discovered with its proprietary technology.

Quintiles and Quest team up for lab testing with $575M JV

Months after LabCorp acquired its rival Covance, Quintiles has signed a sweeping agreement with lab testing giant Quest Diagnostics to launch a joint venture focused on clinical trials.

Parexel buys an Indian CRO with an eye on drug safety

CRO giant Parexel International is acquiring an Indian company devoted to pharmacovigilance, looking to expand its share of the global market for managing drug safety data.

Recipharm pairs up with Adroit for chemistry services

Contract drug developer Recipharm has inked a deal with Adroit Science to join forces in drug formulation.

Ergomed reaches into Asia on the hunt for co-development deals

U.K. contractor Ergomed has made Asian landfall, opening an office in Taiwan with eyes on forging traditional CRO deals and signing risk-sharing agreements with drugmakers.

BioClinica expands in NC after a string of buyouts

Clinical trial service provider BioClinica is stretching out in the biopharma hotbed of Research Triangle Park, NC, opening a new operation to play a bigger role in drug development in the region.

Icon taps Carnegie Mellon to help patients better understand trials

When patients sign up for a clinical trial, how well do they understand the risks, requirements and restrictions that come with it? Icon, a global CRO that handles thousands of studies a year, is working with behavioral scientists at Carnegie Mellon University to study how investigators can improve the informed consent process.

Quintiles taps Google partner Tute Genomics for R&D

Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.

Trial tech outfit Clinical Ink merges with app upstart

Clinical Ink, a provider of trial data software, is merging with Boston's CentrosHealth in hopes of expanding its platform for paperless studies.

PPD cozies up to trial site group with an eye on enrollment

PPD's Acurian subsidiary has expanded its relationship with the Society for Clinical Research Sites, a group representing thousands of trial outposts around the globe, focusing on improving patient recruitment.

Catalent shakes up its business with an eye on product launches

Catalent is merging a few of its core business units in hopes of better focusing on getting its clients' drugs onto the market and pulling off smooth launches.

Evotec pairs up with Second Genome to gut out some R&D

Hybrid researcher Evotec has signed a deal with microbiomics biotech Second Genome to lend out its drug discovery capabilities in hopes of crafting treatments that harness the power of the gut.

WuXi dives into the CAR-T fray with new plant plans

WuXi PharmaTech, China's largest CRO, is positioning itself to cash in on the fervor over new immunotherapies for cancer, planning to build a U.S. facility devoted to manufacturing the newfangled cell therapies.

ACRO's advisory council chimes in on Big Pharma's R&D supergroup

The Association of Clinical Research Organizations (ACRO) assembled a group of CRO leaders to advise TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.

Altasciences partners up for early-stage R&D

Canadian CRO conglomerate Altasciences struck a deal with preclinical researcher ITR Laboratories, joining forces to create a discovery-to-development offering for drugmakers.

Contractor Almac gets into the clinic with a candidate of its own

Contract drug developer Almac has reached a milestone in its efforts to develop in-house therapeutics, taking its top prospect into Phase I trials.

Icon doubles down on med tech with latest offering

Global CRO Icon is launching a new service catered to the specific needs of medical device and diagnostic developers, touting one of its recent acquisitions as key to the move.

Patheon snags another CMO amid its global expansion

Contract drug developer Patheon, a year removed from a $2.6 billion merger, is expanding its manufacturing footprint with another acquisition, buying up a South Carolina specialist.

WuXi eyes major growth in 2015 with plans to spend big

WuXi PharmaTech posted a record revenue year in 2014, and China's largest CRO is planning to increase its internal investments in hopes of delivering double-digit growth.

Enteris gets into contract manufacturing with new plant

Enteris BioPharma is looking to make some money on the side of its drug-delivery operation, opening a contract manufacturing facility and scouting for clients.